Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Z-338 Phase 2b in Functional Dyspepsia
NCT00323817Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2006
- Primary completion
- Apr 2009
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- acotiamide
- Conditions
- functional dyspepsia (FD)
01
Overview
Phase 2, randomised, double-blind trial in functional dyspepsia (FD) comparing Z-338 with Placebo (2 arms). Primary endpoint: Global Subject Outcome Assessment at 12 months. Started Apr 2006; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Z-338
Z-338 (Acotiamide) administered orally.
Placebo
Placebo administered orally.
03
Who it enrols
Adult patients with Functional Dyspepsia defined by Rome II criteria, where postprandial fullness and/or early satiety are the most bothersome symptoms.
04
Endpoints
Primary
Global Subject Outcome Assessment
Secondary
Individual Symptom Score
Beyond the preview
Go deeper on NCT00323817.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00323817.